El interés en corto de WORK Medical Tech Gr da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de WORK Medical Tech Gr. Los datos de interés en corto se actualizan cada dos semanas.

WORK Medical Tech Gr (NASDAQ:WOK) Bolsa, Informe de interés en corto

WORK Medical Technology Group Ltd is engaged in manufacturing and selling medical consumables through its wholly owned subsidiaries in the People's Republic of China. The Company's main products include medical face masks, tourniquets, airways, breathing circuits, intubation accessories, anesthesia kits, oxygen masks, suction sets, laryngoscope blades, KN95 masks, and other disposable medical devices, as well as medical equipment.

WORK Medical Technology Group LTD - Class A Ordinary Shares

WORK Medical Technology Group Ltd

<p>Keefe, Bruyette &amp; Woods  analyst Meyer Shields   maintains Selective Insurance Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIGI#NASDAQ">SIGI</a>) with a Market Perform and lowers the price target from $93 to $92.</p>


News

Price Target

Analyst Ratings

SIGI

Keefe, Bruyette & Woods Maintains Market Perform on Selective Insurance Gr, Lowers Price Target to $92

<p>Keefe, Bruyette &amp; Woods  analyst Wood Lay   maintains Seacoast Banking (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBCF#NASDAQ">SBCF</a>) with a Outperform and lowers the price target from $32 to $31.</p>


SBCF

Keefe, Bruyette & Woods Maintains Outperform on Seacoast Banking, Lowers Price Target to $31

<p>Madrigal Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDGL#NASDAQ">MDGL</a>) is preparing to release its quarterly earnings on Thursday, 2025-05-01. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Madrigal Pharmaceuticals to report an <strong>earnings per share</strong> (EPS) of $-3.83.</p>
<p>The market awaits Madrigal Pharmaceuticals's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Earnings History Snapshot</h3>
<p>In the previous earnings release, the company beat EPS by $1.41, leading to a 5.66% drop in the share price the following trading session.</p>
<p>Here's a look at Madrigal Pharmaceuticals's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-4.12</td>
<td>-6.91</td>
<td>-7.54</td>
<td>-6.28</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-2.71</td>
<td>-4.92</td>
<td>-7.10</td>
<td>-7.38</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-6.0%</td>
<td>23.0%</td>
<td>4.0%</td>
<td>-5.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746028969_0.png" alt="eps graph" /></p>
<h3>Madrigal Pharmaceuticals Share Price Analysis</h3>
<p>Shares of Madrigal Pharmaceuticals were trading at $340.8 as of April 29. Over the last 52-week period, shares are up 59.11%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/MDGL/earnings"><strong>To track all earnings releases for Madrigal Pharmaceuticals visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings

MDGL

Uncovering Potential: Madrigal Pharmaceuticals's Earnings Preview

<p><strong>CareTrust REIT</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTRE#NASDAQ">CTRE</a>) is set to give its latest quarterly earnings report on Thursday, 2025-05-01. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that CareTrust REIT will report an <strong>earnings per share</strong> (EPS) of $0.43. </p>
<p>The market awaits CareTrust REIT's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Overview of Past Earnings</h3>
<p>The company's EPS beat by $0.01 in the last quarter, leading to a 3.67% increase in the share price on the following day.</p>
<p>Here's a look at CareTrust REIT's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.39</td>
<td>0.38</td>
<td>0.36</td>
<td>0.37</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.40</td>
<td>0.38</td>
<td>0.36</td>
<td>0.35</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>4.0%</td>
<td>3.0%</td>
<td>1.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746028960_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of CareTrust REIT were trading at $28.79 as of April 29. Over the last 52-week period, shares are up 16.06%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. </p>
<h3>Analyst Observations about CareTrust REIT</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding CareTrust REIT.</p>
<p>The consensus rating for CareTrust REIT is Outperform, based on 3 analyst ratings. With an average one-year price target of $29.67, there's a potential 3.06% upside.</p>
<h3>Comparing Ratings with Peers</h3>
<p>The below comparison of the analyst ratings and average 1-year price targets of Healthcare Realty Trust, American Healthcare REIT and Sabra Health Care REIT, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Neutral trajectory for Healthcare Realty Trust, with an average 1-year price target of $16.5, suggesting a potential 42.69% downside.</li>
<li>Analysts currently favor an Outperform trajectory for American Healthcare REIT, with an average 1-year price target of $35.4, suggesting a potential 22.96% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Sabra Health Care REIT, with an average 1-year price target of $19.0, suggesting a potential 34.0% downside.</li>
</ul>
<h3>Key Findings: Peer Analysis Summary</h3>
<p>The peer analysis summary offers a detailed examination of key metrics for Healthcare Realty Trust, American Healthcare REIT and Sabra Health Care REIT, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>CareTrust REIT</td>
<td>Outperform</td>
<td>16.32%</td>
<td>$58.93M</td>
<td>1.95%</td>
</tr>
<tr>
<td>Healthcare Realty Trust</td>
<td>Neutral</td>
<td>-7.15%</td>
<td>$176.19M</td>
<td>-2.00%</td>
</tr>
<tr>
<td>American Healthcare REIT</td>
<td>Outperform</td>
<td>12.47%</td>
<td>$112.17M</td>
<td>-1.42%</td>
</tr>
<tr>
<td>Sabra Health Care REIT</td>
<td>Neutral</td>
<td>11.60%</td>
<td>$122.51M</td>
<td>1.70%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>CareTrust REIT ranks highest in Revenue Growth among its peers. It also leads in Gross Profit. However, it has the lowest Return on Equity. Overall, CareTrust REIT is positioned favorably compared to its peers in terms of financial performance metrics.</p>
<h3>All You Need to Know About CareTrust REIT</h3>
<p>CareTrust REIT Inc is a self-administered, publicly-traded REIT engaged in the ownership, acquisition, financing, development and leasing of skilled nursing, seniors housing and other healthcare-related properties. The company has one reportable segment consisting of investments in healthcare-related real estate assets. It generates revenues by leasing healthcare-related properties to healthcare operators in triple-net lease arrangements, under which the tenant is solely responsible for the costs related to the property.</p>
<h3>CareTrust REIT's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Positive Revenue Trend:</strong> Examining CareTrust REIT's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>16.32%</strong> as of 31 December, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Real Estate sector.</p>
<p><strong>Net Margin:</strong> CareTrust REIT's net margin excels beyond industry benchmarks, reaching <strong>83.56%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> CareTrust REIT's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>1.95%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> CareTrust REIT's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>1.64%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> CareTrust REIT's debt-to-equity ratio is below the industry average at <strong>0.14</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<p><a href="https://www.benzinga.com/quote/CTRE/earnings"><strong>To track all earnings releases for CareTrust REIT visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


CTRE

Preview: CareTrust REIT's Earnings

<p>RBC Capital  analyst Brian Abrahams   maintains Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) with a Outperform and lowers the price target from $1051 to $943.</p>


REGN

RBC Capital Maintains Outperform on Regeneron Pharmaceuticals, Lowers Price Target to $943

<p>SPX Techs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPXC#NYSE">SPXC</a>) will release its quarterly earnings report on Thursday, 2025-05-01. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate SPX Techs to report an <strong>earnings per share</strong> (EPS) of $1.17.</p>
<p>Investors in SPX Techs are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Performance in Previous Earnings</h3>
<p>During the last quarter, the company reported an EPS missed by $0.00, leading to a 10.91% increase in the share price on the subsequent day.</p>
<p>Here's a look at SPX Techs's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.51</td>
<td>1.36</td>
<td>1.25</td>
<td>1.04</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.51</td>
<td>1.39</td>
<td>1.42</td>
<td>1.25</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>11.0%</td>
<td>-10.0%</td>
<td>1.0%</td>
<td>7.000000000000001%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746028952_0.png" alt="eps graph" /></p>
<h3>SPX Techs Share Price Analysis</h3>
<p>Shares of SPX Techs were trading at $133.83 as of April 29. Over the last 52-week period, shares are up 8.86%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/SPXC/earnings"><strong>To track all earnings releases for SPX Techs visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


SPXC

SPX Techs Earnings Preview

<p>Lumen Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUMN#NYSE">LUMN</a>) will release its quarterly earnings report on Thursday, 2025-05-01. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Lumen Technologies to report an <strong>earnings per share</strong> (EPS) of $-0.27.</p>
<p>The announcement from Lumen Technologies is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Overview of Past Earnings</h3>
<p>The company's EPS beat by $0.14 in the last quarter, leading to a 1.39% drop in the share price on the following day.</p>
<p>Here's a look at Lumen Technologies's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.05</td>
<td>-0.09</td>
<td>-0.06</td>
<td>0</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.09</td>
<td>-0.13</td>
<td>-0.13</td>
<td>-0.04</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-1.0%</td>
<td>19.0%</td>
<td>33.0%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746028945_0.png" alt="eps graph" /></p>
<h3>Tracking Lumen Technologies's Stock Performance</h3>
<p>Shares of Lumen Technologies were trading at $3.57 as of April 29. Over the last 52-week period, shares are up 170.16%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analyst Views on Lumen Technologies</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Lumen Technologies.</p>
<p>The consensus rating for Lumen Technologies is Neutral, derived from 3 analyst ratings. An average one-year price target of $5.25 implies a potential 47.06% upside.</p>
<h3>Comparing Ratings Among Industry Peers</h3>
<p>This comparison focuses on the analyst ratings and average 1-year price targets of Iridium Communications and Globalstar, three major players in the industry, shedding light on their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Neutral trajectory for Iridium Communications, with an average 1-year price target of $31.5, suggesting a potential 782.35% upside.</li>
<li>Analysts currently favor an Buy trajectory for Globalstar, with an average 1-year price target of $43.33, suggesting a potential 1113.73% upside.</li>
</ul>
<h3>Peer Analysis Summary</h3>
<p>In the peer analysis summary, key metrics for Iridium Communications and Globalstar are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lumen Technologies</td>
<td>Neutral</td>
<td>-5.35%</td>
<td>$1.62B</td>
<td>21.09%</td>
</tr>
<tr>
<td>Iridium Communications</td>
<td>Neutral</td>
<td>5.41%</td>
<td>$153.22M</td>
<td>5.55%</td>
</tr>
<tr>
<td>Globalstar</td>
<td>Buy</td>
<td>16.73%</td>
<td>$39.20M</td>
<td>-14.05%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Lumen Technologies ranks at the bottom for Revenue Growth among its peers. It is in the middle for Gross Profit and Return on Equity.</p>
<h3>Get to Know Lumen Technologies Better</h3>
<p>With 450,000 route miles of fiber, Lumen Technologies is one of the United States' largest telecommunications carriers serving global enterprises. Its merger with Level 3 in 2017 and divestiture of much of its incumbent local exchange carrier, or ILEC, business in 2022 have shifted the company's operations away from its legacy consumer business and toward enterprises (now about 75% of revenue). Lumen offers businesses a full menu of communications services, providing colocation and data center services, data transportation, and end-user phone and internet service. On the consumer side, Lumen provides broadband and phone service across 37 states, where it has 4.5 million broadband customers.</p>
<h3>Unraveling the Financial Story of Lumen Technologies</h3>
<p><strong>Market Capitalization:</strong> Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.</p>
<p><strong>Revenue Growth:</strong> Lumen Technologies's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately <strong>-5.35%</strong>. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Communication Services sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of <strong>2.55%,</strong> the company may need to address challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Lumen Technologies's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>21.09%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Lumen Technologies's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>0.25%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> Lumen Technologies's debt-to-equity ratio is notably higher than the industry average. With a ratio of <b>39.14</b>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<p><a href="https://www.benzinga.com/quote/LUMN/earnings"><strong>To track all earnings releases for Lumen Technologies visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


LUMN

A Look Ahead: Lumen Technologies's Earnings Forecast

<p>Wells Fargo  analyst Matthew Akers   maintains Woodward (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WWD#NASDAQ">WWD</a>) with a Equal-Weight and raises the price target from $175 to $193.</p>


Wells Fargo Maintains Equal-Weight on Woodward, Raises Price Target to $193

<p>Ryman Hospitality Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RHP#NYSE">RHP</a>) will release its quarterly earnings report on Thursday, 2025-05-01. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Ryman Hospitality Props to report an <strong>earnings per share</strong> (EPS) of $1.77.</p>
<p>Investors in Ryman Hospitality Props are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Past Earnings Performance</h3>
<p>Last quarter the company missed EPS by $0.03, which was followed by a 5.02% drop in the share price the next day.</p>
<p>Here's a look at Ryman Hospitality Props's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>2.18</td>
<td>1.77</td>
<td>2.30</td>
<td>1.77</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>2.15</td>
<td>1.93</td>
<td>2.78</td>
<td>1.60</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-5.0%</td>
<td>-1.0%</td>
<td>3.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746028936_0.png" alt="eps graph" /></p>
<h3>Tracking Ryman Hospitality Props's Stock Performance</h3>
<p>Shares of Ryman Hospitality Props were trading at $87.37 as of April 29. Over the last 52-week period, shares are down 16.27%.  Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. </p>
<h3>Analyst Insights on Ryman Hospitality Props</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Ryman Hospitality Props.</p>
<p>Analysts have provided Ryman Hospitality Props with 5 ratings, resulting in a consensus rating of Buy. The average one-year price target stands at $120.4, suggesting a potential 37.8% upside.</p>
<h3>Analyzing Analyst Ratings Among Peers</h3>
<p>In this analysis, we delve into the analyst ratings and average 1-year price targets of Apple Hospitality REIT, Park Hotels &amp; Resorts and Sunstone Hotel Invts, three key industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Neutral trajectory for Apple Hospitality REIT, with an average 1-year price target of $16.0, suggesting a potential 81.69% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Park Hotels &amp; Resorts, with an average 1-year price target of $12.67, suggesting a potential 85.5% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Sunstone Hotel Invts, with an average 1-year price target of $9.6, suggesting a potential 89.01% downside.</li>
</ul>
<h3>Peer Metrics Summary</h3>
<p>The peer analysis summary offers a detailed examination of key metrics for Apple Hospitality REIT, Park Hotels &amp; Resorts and Sunstone Hotel Invts, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ryman Hospitality Props</td>
<td>Buy</td>
<td>2.30%</td>
<td>$182.58M</td>
<td>12.49%</td>
</tr>
<tr>
<td>Apple Hospitality REIT</td>
<td>Neutral</td>
<td>6.59%</td>
<td>$108.16M</td>
<td>0.91%</td>
</tr>
<tr>
<td>Park Hotels &amp; Resorts</td>
<td>Neutral</td>
<td>-4.87%</td>
<td>$162M</td>
<td>1.76%</td>
</tr>
<tr>
<td>Sunstone Hotel Invts</td>
<td>Neutral</td>
<td>-2.03%</td>
<td>$96.75M</td>
<td>-0.17%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Ryman Hospitality Props ranks highest in Gross Profit and Return on Equity among its peers. It is in the middle for Revenue Growth.</p>
<h3>Discovering Ryman Hospitality Props: A Closer Look</h3>
<p>Ryman Hospitality Properties Inc is a lodging and hospitality real estate investment trust that specializes in upscale convention center resorts and country music entertainment experiences. Its core holdings are Gaylord Opryland Resort &amp; Convention Center; Gaylord Palms Resort &amp; Convention Center; Gaylord Texan Resort &amp; Convention Center; Gaylord National Resort &amp; Convention Center; and Gaylord Rockies Resort &amp; Convention Center. The company has three business segments: Hospitality, which includes Gaylord Hotels properties, the Inn at Opryland, and the AC Hotel, Entertainment which includes the entertainment and media assets comprising OEG, and Corporate and Other, which includes corporate expenses. It derives the vast majority of its revenue from its Hospitality segment.</p>
<h3>Breaking Down Ryman Hospitality Props's Financial Performance</h3>
<p><strong>Market Capitalization:</strong> Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Ryman Hospitality Props's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>2.3%</strong> as of 31 December, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Real Estate sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> Ryman Hospitality Props's net margin is impressive, surpassing industry averages. With a net margin of <strong>10.62%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Ryman Hospitality Props's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>12.49%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Ryman Hospitality Props's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>1.32%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> Ryman Hospitality Props's debt-to-equity ratio is notably higher than the industry average. With a ratio of <b>6.4</b>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<p><a href="https://www.benzinga.com/quote/RHP/earnings"><strong>To track all earnings releases for Ryman Hospitality Props visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


What's Next: Ryman Hospitality Props's Earnings Preview

<p><a href="https://www.marijuanamoment.net/trumps-pick-to-lead-dea-says-marijuana-rescheduling-review-will-be-one-of-my-first-priorities-in-the-job/" title="https://www.marijuanamoment.net/trumps-pick-to-lead-dea-says-marijuana-rescheduling-review-will-be-one-of-my-first-priorities-in-the-job/">https://www.marijuanamoment.net/trumps-pick-to-lead-dea-says-marijuana-rescheduling-review-will-be-one-of-my-first-priorities-in-the-job/</a></p>


Biotech

Macro Economic Events

Politics

Economics

General

AKAN

CRON

GRWG

IMCC

LFLY

MSOS

SNDL

TLRY

"Trump's Pick To Lead DEA Says Marijuana Rescheduling Review Will Be 'One Of My First Priorities' In The Job" - Marijuana Moment

<p>Select Medical Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEM#NYSE">SEM</a>) will release its quarterly earnings report on Thursday, 2025-05-01. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Select Medical Hldgs to report an <strong>earnings per share</strong> (EPS) of $0.45.</p>
<p>The market awaits Select Medical Hldgs's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Earnings History Snapshot</h3>
<p>During the last quarter, the company reported an EPS missed by $0.06, leading to a 7.24% drop in the share price on the subsequent day.</p>
<p>Here's a look at Select Medical Hldgs's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.24</td>
<td>0.43</td>
<td>0.61</td>
<td>0.57</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.18</td>
<td>0.50</td>
<td>0.60</td>
<td>0.77</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-7.000000000000001%</td>
<td>12.0%</td>
<td>-13.0%</td>
<td>10.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746028927_0.png" alt="eps graph" /></p>
<h3>Tracking Select Medical Hldgs's Stock Performance</h3>
<p>Shares of Select Medical Hldgs were trading at $18.41 as of April 29. Over the last 52-week period, shares are up 18.04%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/SEM/earnings"><strong>To track all earnings releases for Select Medical Hldgs visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Examining the Future: Select Medical Hldgs's Earnings Outlook

<p>Keefe, Bruyette &amp; Woods  analyst Damon Delmonte   maintains Park Ntl (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PRK#AMEX">PRK</a>) with a Market Perform and raises the price target from $167 to $170.</p>


Keefe, Bruyette & Woods Maintains Market Perform on Park Ntl, Raises Price Target to $170

<p><strong>Bio-Rad Laboratories</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIO#NYSE">BIO</a>) is set to give its latest quarterly earnings report on Thursday, 2025-05-01. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Bio-Rad Laboratories will report an <strong>earnings per share</strong> (EPS) of $1.79. </p>
<p>Bio-Rad Laboratories bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Earnings History Snapshot</h3>
<p>Last quarter the company beat EPS by $0.02, which was followed by a 9.53% drop in the share price the next day.</p>
<p>Here's a look at Bio-Rad Laboratories's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>2.88</td>
<td>1.16</td>
<td>2.01</td>
<td>2.15</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>2.90</td>
<td>2.01</td>
<td>3.11</td>
<td>2.29</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-10.0%</td>
<td>8.0%</td>
<td>-2.0%</td>
<td>-4.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746028911_0.png" alt="eps graph" /></p>
<h3>Tracking Bio-Rad Laboratories's Stock Performance</h3>
<p>Shares of Bio-Rad Laboratories were trading at $242.32 as of April 29. Over the last 52-week period, shares are down 13.94%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<h3>Insights Shared by Analysts on Bio-Rad Laboratories</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Bio-Rad Laboratories.</p>
<p>Bio-Rad Laboratories has received a total of 2 ratings from analysts, with the consensus rating as Neutral. With an average one-year price target of $307.5, the consensus suggests a potential 26.9% upside.</p>
<h3>Comparing Ratings with Peers</h3>
<p>The following analysis focuses on the analyst ratings and average 1-year price targets of Bruker, Charles River and Stevanato Group, three prominent industry players, providing insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Outperform trajectory for Bruker, with an average 1-year price target of $57.0, suggesting a potential 76.48% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Charles River, with an average 1-year price target of $166.8, suggesting a potential 31.17% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Stevanato Group, with an average 1-year price target of $23.5, suggesting a potential 90.3% downside.</li>
</ul>
<h3>Comprehensive Peer Analysis Summary</h3>
<p>The peer analysis summary offers a detailed examination of key metrics for Bruker, Charles River and Stevanato Group, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bio-Rad Laboratories</td>
<td>Neutral</td>
<td>-2.00%</td>
<td>$341.91M</td>
<td>-10.18%</td>
</tr>
<tr>
<td>Bruker</td>
<td>Outperform</td>
<td>14.64%</td>
<td>$493.30M</td>
<td>0.76%</td>
</tr>
<tr>
<td>Charles River</td>
<td>Neutral</td>
<td>-1.08%</td>
<td>$284.24M</td>
<td>-5.96%</td>
</tr>
<tr>
<td>Stevanato Group</td>
<td>Neutral</td>
<td>3.10%</td>
<td>$98.15M</td>
<td>3.54%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Bio-Rad Laboratories ranks in the middle among peers for consensus rating. It ranks at the bottom for revenue growth and gross profit, while it ranks at the top for return on equity.</p>
<h3>Unveiling the Story Behind Bio-Rad Laboratories</h3>
<p>Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (56% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (44% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (42% of 2023 sales), Europe (31%), Asia (31%), and other (6%). Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.</p>
<h3>Financial Milestones: Bio-Rad Laboratories's Journey</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Revenue Challenges:</strong> Bio-Rad Laboratories's revenue growth over 3 months faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately <strong>-2.0%</strong>. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Bio-Rad Laboratories's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>-107.24%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Bio-Rad Laboratories's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>-10.18%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>-7.17%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.21</strong>.</p>
<p><a href="https://www.benzinga.com/quote/BIO/earnings"><strong>To track all earnings releases for Bio-Rad Laboratories visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


A Preview Of Bio-Rad Laboratories's Earnings

<p>Amicus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOLD#NASDAQ">FOLD</a>) is gearing up to announce its quarterly earnings on Thursday, 2025-05-01. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Amicus Therapeutics will report an <strong>earnings per share</strong> (EPS) of $0.08.</p>
<p>The announcement from Amicus Therapeutics is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Past Earnings Performance</h3>
<p>In the previous earnings release, the company missed EPS by $0.00, leading to a 5.13% drop in the share price the following trading session.</p>
<p>Here's a look at Amicus Therapeutics's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.09</td>
<td>0</td>
<td>-0.05</td>
<td>-0.07</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.09</td>
<td>0.1</td>
<td>0.06</td>
<td>-0.02</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-5.0%</td>
<td>-2.0%</td>
<td>1.0%</td>
<td>-3.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746028887_0.png" alt="eps graph" /></p>
<h3>Performance of Amicus Therapeutics Shares</h3>
<p>Shares of Amicus Therapeutics were trading at $7.52 as of April 29. Over the last 52-week period, shares are down 27.89%.  Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. </p>
<h3>Analyst Views on Amicus Therapeutics</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Amicus Therapeutics.</p>
<p>A total of 1 analyst ratings have been received for Amicus Therapeutics, with the consensus rating being Outperform. The average one-year price target stands at $17.0, suggesting a potential 126.06% upside.</p>
<h3>Understanding Analyst Ratings Among Peers</h3>
<p>The analysis below examines the analyst ratings and average 1-year price targets of Recursion Pharmaceuticals, Apellis Pharmaceuticals and Twist Bioscience, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Buy trajectory for Recursion Pharmaceuticals, with an average 1-year price target of $9.0, suggesting a potential 19.68% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Apellis Pharmaceuticals, with an average 1-year price target of $38.89, suggesting a potential 417.15% upside.</li>
<li>Analysts currently favor an Outperform trajectory for Twist Bioscience, with an average 1-year price target of $50.25, suggesting a potential 568.22% upside.</li>
</ul>
<h3>Summary of Peers Analysis</h3>
<p>Within the peer analysis summary, vital metrics for Recursion Pharmaceuticals, Apellis Pharmaceuticals and Twist Bioscience are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amicus Therapeutics</td>
<td>Outperform</td>
<td>30.09%</td>
<td>$134.87M</td>
<td>7.91%</td>
</tr>
<tr>
<td>Recursion Pharmaceuticals</td>
<td>Buy</td>
<td>-57.54%</td>
<td>$-8.28M</td>
<td>-22.95%</td>
</tr>
<tr>
<td>Apellis Pharmaceuticals</td>
<td>Neutral</td>
<td>45.19%</td>
<td>$171.67M</td>
<td>-15.61%</td>
</tr>
<tr>
<td>Twist Bioscience</td>
<td>Outperform</td>
<td>24.08%</td>
<td>$42.84M</td>
<td>-6.80%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Amicus Therapeutics ranks at the top for Revenue Growth and Gross Profit among its peers. However, it ranks at the bottom for Return on Equity.</p>
<h3>Unveiling the Story Behind Amicus Therapeutics</h3>
<p>Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.</p>
<h3>Amicus Therapeutics's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<p><strong>Revenue Growth:</strong> Amicus Therapeutics's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately <strong>30.09%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Amicus Therapeutics's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>9.85%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Amicus Therapeutics's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>7.91%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Amicus Therapeutics's ROA excels beyond industry benchmarks, reaching <strong>1.88%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Amicus Therapeutics's debt-to-equity ratio is notably higher than the industry average. With a ratio of <b>2.29</b>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<p><a href="https://www.benzinga.com/quote/FOLD/earnings"><strong>To track all earnings releases for Amicus Therapeutics visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


FOLD

Amicus Therapeutics Earnings Preview

<p><a href="https://www.benzinga.com/topic/donald-trump">President <strong>Donald Trump</strong></a> took to Truth Social on Wednesday to distance himself from the current state of the stock market, reminding followers, <em>"</em>This is Biden's Stock Market, not Trump's."</p>
<p>Trump, who began his term on Jan. 20, <a href="https://truthsocial.com/@realDonaldTrump/posts/114427089568235019">said</a> the current downturn "has NOTHING TO DO WITH TARIFFS" and pointed instead to what he called the lingering "Biden overhang."</p>
<p>"Be patient!" Trump added, asserting that a boom is coming once the hangover from the previous administration clears. He also claimed companies are "starting to move into the USA in record numbers," citing optimism around his economic plans— especially tariffs, which he said "will soon start kicking in."</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/economics/macro-economic-events/25/04/45100047/recession-odds-spike-wall-street-tumbles-as-q1-gdp-surprisingly-contracts-be-patient-trump-responds">Recession Odds Spike, Wall Street Tumbles As Q1 GDP Surprisingly Contracts: &#8216;Be Patient,&#8217; Trump Responds</a></strong></p>
<p>The former president's post comes as the S&amp;P 500 has declined 7.92% over the past three months. Consumer Discretionary stocks have seen the steepest drop, down 13.8%, while Technology shares have fallen nearly 10%. Even the Energy sector, which Trump has vocally supported, is down 7.77% in the same period. </p>
<p>Only Consumer Staples (+2.90%) and Utilities (+3.34%) have managed gains during this stretch.</p>
<p>Year-to-date, the <strong>SPDR S&amp;P 500 ETF</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) is down over 7%, retreating from a 52-week high of $613.23 to trade at $543.29 as of April 30.</p>
<p>Trump made no mention of specific stock sectors or companies but emphasized that the current trajectory would shift, saying, "when the boom begins, it will be like no other."</p>
<p><strong>Read Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/45098124/trumps-next-100-days-these-fallen-angels-are-jpmorgans-top-picks">Trump&#8217;s Next 100 Days: These &#8216;Fallen Angels&#8217; Are JPMorgan&#8217;s Top Picks</a></strong></li>
</ul>
<p><em>Photo: noamgalai via Shutterstock</em></p>


Government

Broad U.S. Equity ETFs

ETFs

Trump Labels Market Decline 'Biden's Stock Market' As He Distances Tariffs From Downturn

<p>Trinity Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRN#NYSE">TRN</a>) is gearing up to announce its quarterly earnings on Thursday, 2025-05-01. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Trinity Industries will report an <strong>earnings per share</strong> (EPS) of $0.33.</p>
<p>The market awaits Trinity Industries's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Overview of Past Earnings</h3>
<p>The company's EPS beat by $0.05 in the last quarter, leading to a 3.64% drop in the share price on the following day.</p>
<p>Here's a look at Trinity Industries's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.34</td>
<td>0.38</td>
<td>0.33</td>
<td>0.22</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.39</td>
<td>0.43</td>
<td>0.66</td>
<td>0.33</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-4.0%</td>
<td>-5.0%</td>
<td>-7.000000000000001%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746028875_0.png" alt="eps graph" /></p>
<h3>Performance of Trinity Industries Shares</h3>
<p>Shares of Trinity Industries were trading at $25.05 as of April 29. Over the last 52-week period, shares are down 17.94%.  Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. </p>
<h3>Analyst Observations about Trinity Industries</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Trinity Industries.</p>
<p>The consensus rating for Trinity Industries is Neutral, derived from 3 analyst ratings. An average one-year price target of $30.0 implies a potential 19.76% upside.</p>
<h3>Comparing Ratings Among Industry Peers</h3>
<p>The following analysis focuses on the analyst ratings and average 1-year price targets of Terex, Greenbrier Companies and Atmus Filtration Techs, three prominent industry players, providing insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Neutral trajectory for Terex, with an average 1-year price target of $43.9, suggesting a potential 75.25% upside.</li>
<li>Analysts currently favor an Outperform trajectory for Greenbrier Companies, with an average 1-year price target of $52.0, suggesting a potential 107.58% upside.</li>
<li>Analysts currently favor an Outperform trajectory for Atmus Filtration Techs, with an average 1-year price target of $42.4, suggesting a potential 69.26% upside.</li>
</ul>
<h3>Analysis Summary for Peers</h3>
<p>The peer analysis summary offers a detailed examination of key metrics for Terex, Greenbrier Companies and Atmus Filtration Techs, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trinity Indus</td>
<td>Neutral</td>
<td>-21.12%</td>
<td>$155M</td>
<td>2.73%</td>
</tr>
<tr>
<td>Terex</td>
<td>Neutral</td>
<td>1.47%</td>
<td>$197M</td>
<td>-0.11%</td>
</tr>
<tr>
<td>Greenbrier Companies</td>
<td>Outperform</td>
<td>-11.66%</td>
<td>$138.60M</td>
<td>3.61%</td>
</tr>
<tr>
<td>Atmus Filtration Techs</td>
<td>Outperform</td>
<td>1.75%</td>
<td>$107.10M</td>
<td>17.88%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Trinity Industries ranks at the bottom for Revenue Growth and Gross Profit, while it is in the middle for Return on Equity.</p>
<h3>All You Need to Know About Trinity Industries</h3>
<p>Trinity Industries Inc. sells and leases railroad products and railcar maintenance services in North America. The company operates under the name TrinityRail in three main segments: railcar leasing and management services, which owns railcars and provides fleet management and administration services; rail products, which builds, sells, and modifies freight and tank railcars and their components; and all other, which sells highway products such as guardrail and other highway barriers. Customers include railroads, leasing companies, and shipping companies in agriculture, construction, consumer products, energy, and chemicals.</p>
<h3>A Deep Dive into Trinity Industries's Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Negative Revenue Trend:</strong> Examining Trinity Industries's financials over 3 months reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately <strong>-21.12%</strong> in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Industrials sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Trinity Industries's net margin is impressive, surpassing industry averages. With a net margin of <strong>4.59%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Trinity Industries's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>2.73%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>0.33%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> With a high debt-to-equity ratio of <strong>5.37</strong>, Trinity Industries faces challenges in effectively managing its debt levels, indicating potential financial strain.</p>
<p><a href="https://www.benzinga.com/quote/TRN/earnings"><strong>To track all earnings releases for Trinity Industries visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings Preview For Trinity Industries

<p>Wells Fargo  analyst Tiago Fauth   maintains Verona Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNA#NASDAQ">VRNA</a>) with a Overweight and raises the price target from $93 to $107.</p>


VRNA

Wells Fargo Maintains Overweight on Verona Pharma, Raises Price Target to $107

<p>Schneider National (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNDR#NYSE">SNDR</a>) is preparing to release its quarterly earnings on Thursday, 2025-05-01. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Schneider National to report an <strong>earnings per share</strong> (EPS) of $0.14.</p>
<p>Schneider National bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Earnings History Snapshot</h3>
<p>During the last quarter, the company reported an EPS missed by $0.00, leading to a 1.46% drop in the share price on the subsequent day.</p>
<p>Here's a look at Schneider National's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.2</td>
<td>0.23</td>
<td>0.18</td>
<td>0.12</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.2</td>
<td>0.18</td>
<td>0.21</td>
<td>0.11</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-1.0%</td>
<td>0.0%</td>
<td>-1.0%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746028865_0.png" alt="eps graph" /></p>
<h3>Performance of Schneider National Shares</h3>
<p>Shares of Schneider National were trading at $21.7 as of April 29. Over the last 52-week period, shares are down 2.56%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. </p>
<h3>Analysts' Take on Schneider National</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Schneider National.</p>
<p>With 12 analyst ratings, Schneider National has a consensus rating of Neutral. The average one-year price target is $27.17, indicating a potential 25.21% upside.</p>
<h3>Comparing Ratings with Peers</h3>
<p>This comparison focuses on the analyst ratings and average 1-year price targets of Landstar System, RXO and Ryder System, three major players in the industry, shedding light on their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Neutral trajectory for Landstar System, with an average 1-year price target of $146.22, suggesting a potential 573.82% upside.</li>
<li>Analysts currently favor an Neutral trajectory for RXO, with an average 1-year price target of $20.64, suggesting a potential 4.88% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Ryder System, with an average 1-year price target of $163.0, suggesting a potential 651.15% upside.</li>
</ul>
<h3>Snapshot: Peer Analysis</h3>
<p>The peer analysis summary provides a snapshot of key metrics for Landstar System, RXO and Ryder System, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Schneider National</td>
<td>Neutral</td>
<td>-2.38%</td>
<td>$128M</td>
<td>1.09%</td>
</tr>
<tr>
<td>Landstar System</td>
<td>Neutral</td>
<td>0.41%</td>
<td>$153.79M</td>
<td>4.65%</td>
</tr>
<tr>
<td>RXO</td>
<td>Neutral</td>
<td>70.45%</td>
<td>$227M</td>
<td>-1.53%</td>
</tr>
<tr>
<td>Ryder System</td>
<td>Neutral</td>
<td>0.71%</td>
<td>$616M</td>
<td>3.20%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Schneider National ranks at the bottom for Revenue Growth among its peers. It is in the middle for Gross Profit. For Return on Equity, it is also in the middle.</p>
<h3>Get to Know Schneider National Better</h3>
<p>Schneider National Inc is a provider of surface transportation and logistics solutions in North America. The Company offers truckload, intermodal, and logistics services to a diverse customer base throughout the continental United States, Canada, and Mexico. The company's segments include Truckload; Intermodal; Logistics and other. It generates maximum revenue from the Truckload segment.</p>
<h3>Financial Insights: Schneider National</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Challenges:</strong> Schneider National's revenue growth over 3 months faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately <strong>-2.38%</strong>. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Industrials sector.</p>
<p><strong>Net Margin:</strong> Schneider National's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>2.43%,</strong> the company may encounter challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Schneider National's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>1.09%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Schneider National's ROA excels beyond industry benchmarks, reaching <strong>0.69%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Schneider National's debt-to-equity ratio is below the industry average. With a ratio of <b>0.18</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<p><a href="https://www.benzinga.com/quote/SNDR/earnings"><strong>To track all earnings releases for Schneider National visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


SNDR

A Look Ahead: Schneider National's Earnings Forecast

<p><strong>Linde</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIN#NASDAQ">LIN</a>) is set to give its latest quarterly earnings report on Thursday, 2025-05-01. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Linde will report an <strong>earnings per share</strong> (EPS) of $3.92. </p>
<p>The announcement from Linde is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Historical Earnings Performance</h3>
<p>In the previous earnings release, the company beat EPS by $0.05, leading to a 1.22% drop in the share price the following trading session.</p>
<p>Here's a look at Linde's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>3.92</td>
<td>3.89</td>
<td>3.78</td>
<td>3.42</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>3.97</td>
<td>3.94</td>
<td>3.85</td>
<td>3.75</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-1.0%</td>
<td>0.0%</td>
<td>0.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746028853_0.png" alt="eps graph" /></p>
<h3>Performance of Linde Shares</h3>
<p>Shares of Linde were trading at $450.58 as of April 29. Over the last 52-week period, shares are up 7.85%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/LIN/earnings"><strong>To track all earnings releases for Linde visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


A Look at Linde's Upcoming Earnings Report

<p>Financial giants have made a conspicuous bullish move on ServiceNow. Our analysis of options history for ServiceNow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>) revealed 23 unusual trades.</p>
<p>Delving into the details, we found 39% of traders were bullish, while 26% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $821,440, and 19 were calls, valued at $1,375,473.</p>
<h3>Projected Price Targets</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $650.0 to $1100.0 for ServiceNow during the past quarter. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for ServiceNow's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of ServiceNow's whale trades within a strike price range from $650.0 to $1100.0 in the last 30 days. </p>
<h3>ServiceNow Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746028840_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>NOW</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/17/27</td>
<td>$93.0</td>
<td>$85.2</td>
<td>$89.0</td>
<td>$750.00</td>
<td>$667.5K</td>
<td align="right">0</td>
<td align="right">75</td>
</tr>
<tr>
<td>NOW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$58.1</td>
<td>$57.2</td>
<td>$57.2</td>
<td>$1000.00</td>
<td>$343.2K</td>
<td align="right">101</td>
<td align="right">81</td>
</tr>
<tr>
<td>NOW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$180.6</td>
<td>$168.2</td>
<td>$176.0</td>
<td>$930.00</td>
<td>$176.0K</td>
<td align="right">21</td>
<td align="right">10</td>
</tr>
<tr>
<td>NOW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$189.9</td>
<td>$188.3</td>
<td>$189.9</td>
<td>$840.00</td>
<td>$132.9K</td>
<td align="right">65</td>
<td align="right">8</td>
</tr>
<tr>
<td>NOW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/02/25</td>
<td>$11.0</td>
<td>$10.3</td>
<td>$11.0</td>
<td>$950.00</td>
<td>$89.1K</td>
<td align="right">490</td>
<td align="right">222</td>
</tr>
</tbody>
</table>
</p>
<h3>About ServiceNow</h3>
<p>ServiceNow Inc provides software solutions to structure and automate various business processes via a SaaS delivery model. The company primarily focuses on the IT function for enterprise customers. ServiceNow began with IT service management, expanded within the IT function, and more recently directed its workflow automation logic to functional areas beyond IT, notably customer service, HR service delivery, and security operations. ServiceNow also offers an application development platform as a service.</p>
<p>Following our analysis of the options activities associated with ServiceNow, we pivot to a closer look at the company's own performance.</p>
<h3>Where Is ServiceNow Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 487,407, the NOW's price is up by 0.18%, now at $944.55. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 84 days.</li>
</ul>
<h3>What Analysts Are Saying About ServiceNow</h3>
<p>In the last month, 5 experts released ratings on this stock with an average target price of $986.2.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Evercore ISI Group has decided to maintain their Outperform rating on ServiceNow, which currently sits at a price target of $1000.<br />
&#x2A; Maintaining their stance, an analyst from UBS continues to hold a Buy rating for ServiceNow, targeting a price of $1025.<br />
&#x2A; Consistent in their evaluation, an analyst from Canaccord Genuity keeps a Buy rating on ServiceNow with a target price of $1075.<br />
&#x2A; Consistent in their evaluation, an analyst from Morgan Stanley keeps a Equal-Weight rating on ServiceNow with a target price of $950.<br />
&#x2A; Maintaining their stance, an analyst from Morgan Stanley continues to hold a Equal-Weight rating for ServiceNow, targeting a price of $881. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest ServiceNow options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>


Options

Markets

ServiceNow's Options Frenzy: What You Need to Know

Press Releases

WORK Medical Technology Group LTD Announces Pricing of Initial Public Offering

Kingswood Capital Partners, LLC Announces Pricing of $8 Million Initial Public Offering of Ordinary Shares for its Client WORK Medical Technology Group LTD. (Nasdaq: WOK)

Comments

WORK Medical Tech Gr

Interés en corto

WORK Medical Tech Gr (NASDAQ:WOK) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL